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Abstract
Genetic factors influence the effects of fluoride (F) on amelogenesis and bone
homeostasis but the underlying molecular mechanisms remain undefined. A label-
free proteomics approach was employed to identify and evaluate changes in bone
protein expression in two mouse strains having different susceptibilities to develop
dental fluorosis and to alter bone quality. In vivo bone formation and
histomorphometry after F intake were also evaluated and related to the proteome.
Resistant 129P3/J and susceptible A/J mice were assigned to three groups given
low-F food and water containing 0, 10 or 50 ppmF for 8 weeks. Plasma was
evaluated for alkaline phosphatase activity. Femurs, tibiae and lumbar vertebrae
were evaluated using micro-CT analysis and mineral apposition rate (MAR) was
measured in cortical bone. For quantitative proteomic analysis, bone proteins were
extracted and analyzed using liquid chromatography-electrospray ionization-
tandem mass spectrometry (LC-ESI-MS/MS), followed by label-free semi-
quantitative differential expression analysis. Alterations in several bone proteins
were found among the F treatment groups within each mouse strain and between
the strains for each F treatment group (ratio $1.5 or #0.5; p,0.05). Although F
treatment had no significant effects on BMD or bone histomorphometry in either
strain, MAR was higher in the 50 ppmF 129P3/J mice than in the 50 ppmFA/J mice
treated with 50 ppmF showing that F increased bone formation in a strain-specific
manner. Also, F exposure was associated with dose-specific and strain-specific
alterations in expression of proteins involved in osteogenesis and
osteoclastogenesis. In conclusion, our findings confirm a genetic influence in bone
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response to F exposure and point to several proteins that may act as targets for the
differential F responses in this tissue.
Introduction
Fluoride (F) is readily absorbed from the stomach and small intestine, followed by
its deposition in calcified tissues and urinary excretion [1]. The anabolic effect of
F on bone mass has been studied for many years, but there is still controversy
about the quality of the bone formed [2, 3]. Evaluation of the efficacy of F therapy
is complicated, since it can have a biphasic dose-dependent response on bone
cells, i.e., stimulating bone formation at a low dose and being toxic at a high dose
[4, 5]. The effectiveness of F therapy for osteoporosis could depend on earlier
administration of low-dose regimens in which toxic levels are avoided and
mineralization is not affected [6].
Although the dose of F is highly relevant, it is not the only factor influencing the
effects of F on bone. Approximately one third of patients receiving F therapy for
osteoporosis are non-responders [7]. Furthermore, about 40% of the population
living in areas with naturally high F levels in water were not affected by skeletal
fluorosis [8] and 5% of children in high F areas had no dental fluorosis (DF) [9].
The sensitivity of trabecular bone to both anabolic and catabolic stimuli is
influenced by genetics and this could explain, in part, why treatments with F for
low bone mass are not universally effective [10].
The influence of genetic background in F-induced responses is also supported
by studies comparing different mouse strains. Differences in DF susceptibility/
resistance among 12 inbred strains of mice have been observed [11]. Compared to
the other strains tested, the A/J strain was highly susceptible, rapidly developing
severe DF, while the 129P3/J strain was more resistant, exhibiting only slight
degrees of DF [11, 12]. The A/J and 129P3/J mice also have a differential bone
response to F. Increasing F doses (0, 25, 50 and 100 ppm) for these mouse strains
had different effects on the mechanical properties of both cortical and trabecular
bone. Mechanical testing showed remarkable reduction in bone quality in the A/J
strain after receiving F, whereas no significant effect in the 129P3/J strain was
observed [13]. This was not related to a reduction in F uptake by bone, since
previous work from our laboratory has shown that the femur F concentrations
were higher in the 129P3/J strain than in the A/J strain [12]. In additional study,
beyond the physical and chemical effects on bone mineral, treatment with
100 ppmF in drinking water significantly increased osteoid volume and osteoid
area for both strains [14]. The increase in osteoid formation supports the
observation that F induces osteoblastic activity and delays mineralization of newly
formed bone.
The present study was designed to investigate the effects of F on bone and the
molecular mechanisms that could account for the effects. We used label-free
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quantitative proteomic analysis complemented by static and dynamic histomor-
phometry. We chose the A/J and 129P3/J strains of mice as the models since, as
discussed above, they have been shown to have distinctly different responses to
fluoride exposure. We concluded that F exposure at high levels enhanced bone
formation in 129P3/J mice, but not in A/J mice, confirming a genetic influence in
the response of bone to F. Several proteins could account for the strain-specific
skeletal phenotype after F exposure.
Materials and Methods
Mice and Fluoride Treatment
The research protocol was approved by the Institutional Animal Care and Use
Committee of the University of São Paulo, Bauru Dental School. Weanling (21
days old) male 129P3/J and A/J mice were obtained from the Jackson Laboratory
(Bar Harbor, ME, USA) and randomly distributed into three groups given low-F
diet (0.95 ppm F, AIN76A, PMI Nutrition, Richmond, IN, USA) and water
containing 10 or 50 ppmF added as NaF for 8 weeks. They led to plasma F levels
corresponding to those found in humans drinking water containing 1 (optimally
fluoridated areas) and 10 mg/L F (areas of endemic fluorosis), respectively [15].
Control groups received water without F. Each group consisted of 32 mice, 16
from each strain. Plasma was collected for alkaline phosphatase (ALP) activity.
Femurs, tibiae, and lumbar vertebrae were harvested, and cleaned of soft tissues.
Some bones were fixed in 95% v/v ethanol and stored in 70% v/v ethanol at 4 C̊.
Others were snap frozen in liquid N2 and stored at 280 C̊ until used.
Micro-CT analysis
Femurs, tibiae and 4th lumbar vertebrae were subjected to micro-CT analysis
(n58/group). Bones were scanned using the Skyscan 1074HR microCT (Skyscan,
Aartselaar, Belgium) at the resolution of 20.7 mm/pixel. Standardized scanning
and image reconstruction settings fully automated were used. Hydroxyapatite
phantoms (250 mg/cc and 750 mg/cc) (CIRS, Inc., Norfolk, VA) were used to
determine bone mineral densities within regions and volumes of interest.
Morphometric parameters were calculated by CT-analyser (v1.9.1.0, Skyscan,
Kontich, Belgium) either in 3D based on a volume model, or in 2D from cross-
sectional images. Trabecular regions of the proximal tibiae and L4 vertebrae were
used to determine bone mineral density (BMD), bone volume fraction (BV/TV),
specific bone surface (BS/BV), bone surface density (BS/TV), trabecular thickness
(Tb.Th), trabecular separation (Tb.Sp), trabecular number (Tb.N), and trabecular
bone pattern factor (Pb.Pf). One mm cortical regions within the mid-diaphysis of
the femurs were used to determine mean total cross-sectional bone area (B.Ar),
mean total cross-sectional bone perimeter (B.Pm), mean total cross-sectional
tissue area (T.Ar), mean total cross-sectional tissue perimeter (T.Pm), mean polar
moment of inertia (MMI), and cortical BMD.
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Mineral Apposition Rate (MAR)
Mice (n58/group) were injected intraperitoneally with calcein (10 mg/Kg in 2%
sodium bicarbonate, 0.1 mL/mouse) at 7 days prior to euthanasia and Alizarin
Complexone (30 mg/Kg in 2% sodium bicarbonate, 0.1 mL/mouse) 2 days prior
to euthanasia. Bones were dried to touch and embedded in epoxy, Pelco Eponate
12 (25.7 mL resin +9.3 mL DDSA +16.5 mL NMA +1.6 mL BDMA) (Ted Pella,
Inc., Redding, CA, USA). After 24 h cure at 60 C̊, samples were sawed using a
Buehler Isomet Low Speed saw (Buehler Inc., Lake Bluff, IL, USA) equipped with
a diamond wafer saw blade and 200–300 micron thick sections were cemented to
glass slides. Mounted sections were ground using 600-C silicon carbide wet paper
(Mager Scientific Inc., Dexter, MI, USA) to a final thickness of 100 microns.
Calcein and alizarin complexone fluorophores were visualized at 100X and 400X
using epifluorescence microscopy, Nikon Eclipse 50i equipped with a XF52 dual
band filter set (excitation at 490 and 550, dichroic 490–550 and emitter at 520 and
580) (Omega Optical, Brattleboro, VT, USA). Images were captured using a
Nikon DXM1200 camera and ACT-1 software (Nikon Instruments Inc., Melville,
NY, USA).
Protein Extraction/Sample preparation
Protein extraction was performed according to the method described by
Domenicucci et al. [16] with a slight modification. Frozen femurs (n58/group)
were ground with a mortar and pestle. All of the following steps were performed
at 4 C̊ with constant stirring. The bone chips were washed in PBS with protease
inhibitors (three times for a total of 24 h) to extract bone marrow proteins. After
centrifugation, the supernatant was collected as PBS Extract. The pellet was
treated four times with G-buffer (4 M guanidine HCl, 50 mM Tris/HCl, pH 7.4
containing protease inhibitors). The supernatant was collected as G1 Extract after
centrifugation. The residue was then washed three times in PBS containing
protease inhibitors, followed by four times steps of extraction with E- buffer every
24 hours each (0.5 M EDTA, 50 mM-Tris/HCl, pH 7.4 containing protease
inhibitors) to release mineral-associated proteins. After centrifugation the
supernatant was collected as EDTA Extract. Finally, the pellet was washed three
times in PBS with protease inhibitors and was then extracted again with G-buffer
four times over 96 h. The supernatant was collected as G2 Extract after
centrifugation. To remove the excess of guanidine HCl, G1G2 extracts were
cleaned up using PD MIniTrap G-10 (GE Healthcare, Munich, Germany). Excess
of EDTA and other interfering substances was removed from samples by
centrifugal filtration using the Amicon Ultra-4 Centrifugal Filter Unit with
Ultracel-3 membrane (Millipore, Billerica, MA). These extracts were pooled and
protein concentration was determined by the Pierce BCA protein assay.
Bone Response to Fluoride
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LC MS/MS
For each group, 300 mg of protein were denatured and reduced in a buffer
containing 100 mL of 4 M urea, 10 mM DTT and 50 mM NH4HCO3, pH 7.8 for
1 h at room temperature (RT). Then, the samples were diluted to 1 M urea with
50 mM NH4HCO3, pH 7.8. Finally, trypsin (Trypsin Gold, Promega, Madison,
WI) was added (1:20 w/w), and the solution incubated at 37 C̊ for 18 h. The
extracted peptides were concentrated and desalted with Perfect Pure C18 Tips
(Eppendorf, Hamburg, Germany) and analyzed by LC-ESI-MS/MS. The
Nanoflow HPLC/MS/MS system consists of a Proxeon EasyNano-LC
(ThermoFisher, USA) coupled to LTQ-VELOS-Ion Trap (ThermoFisher, USA)
MS. The nano-LC system includes a 5 mm L.60.3 mm I.D. reverse phase trap
column packed with 5 mm C18 Zorbax 300SB beads (Agilent, USA), and nanoflow
analytical column (150 mm L.60.075 mm I.D. with 0.015 mm tip opening)
packed with the same reversed phase C18 beads as in the Trap column. Peptides
were eluted from the column using a linear gradient profile from 6% Solvent B to
65% solvent B in 30 min, followed by 3 min wash with 95% solvent B (Solvent A:
2% acetonitrile with 0.1% formic acid; Solvent B: 98% acetonitrile with 0.1%
formic acid). The flow rate was set to 300 nL/min with a maximum pressure of
280 bar. Electrospray voltage and the temperature of the ion transfer capillary
were 1.8 kV and 250 C̊ respectively. All samples were analyzed in triplicate,
resulting in 18 LC-MS/MS runs. The acquired MS/MS spectra was searched
against the Mus musculus database from NCBI (Version Dec/2010) using
SEQUEST algorithm in Proteome Discoverer 1.3 software (Thermo Scientific, San
Jose, CA, USA) for protein identification. The minimum number of peptides to
identify proteins was set at two. Search results were filtered for a False Discovery
rate of 1% employing a decoy search strategy utilizing a reverse database. An
additional inclusion criterion for positive identification of proteins was the same
protein passing the filter score in at least two different MS analyses from the same
time-point group in a total of three MS analyses per group. The label-free semi-
quantitative differential expression analysis was performed with SIEVE software
1.3 (Thermo Fisher Scientific, San Jose, CA). Changes in relative protein
abundance between the groups (A/B) were regarded as significant when the ratio
was #0.5 for increase in abundance in B compared to A (B.A) or $1.5 for
decrease in abundance in B compared to A (B,A), and a p-value ,0.05.
Identified bone proteins were classified according to their biological processes and
cellular localization using Web-based Babelomics (http://babelomics.bioinfo.cipf.
es/index.html), MGI Mouse Genome Informatics (http://www.informatics.jax.
org/), and Uniprot protein data base (http://www.informatics.jax.org/).
Plasma ALP activity
The ALP activity was measured in plasma by enzymatic assay using p-nitrophenyl
phosphate (pNPP) as substrate. For the ALP activity assay, 100 mL of a solution
containing 25 mM glycine buffer (pH 9.4), 2 mM MgCl2 and 1 mM p-NPP were
added to 96-well plates. After incubation for 30 min in a water bath, 5 mL of each
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sample (in duplicate) were added. The plate was kept at 37 C̊ for 60 min. Then the
reaction was stopped with 1 M NaOH. The final product (p-nitrophenol) was
quantified at 405 nm (e518,000 M21 cm21) and the results were expressed as
specific activity (nmol p-nitrophenol min21 mg21 of protein).
Western blotting
Four independent experiments were performed with individual sample of each
group, totalizing 4 different samples per group. Mouse femur samples were
extracted as described above. For each group, 30 mg of protein were separated on
10% SDS-PAGE gels and transferred onto a PVDF membrane. After blocking with
1% low-fat milk for 1 h at RT, the membranes were incubated at 4 C̊ overnight
with rabbit polyclonal anti-mouse collagen type I (Millipore, AB765P) and anti-b-
tubulin (Santa Cruz Biotechnology, sc-9104) in 3% BSA and 0.1% TBS-Tween
(TBS-T). The membranes were then washed 3 times for 10 min with 0.1% TBS-T,
and incubated for 1 hour at RT with horseradish peroxidase-conjugated
secondary antibody (GE Healthcare, Buckinghamshire, UK). After washing,
proteins of interest were detected using the enhanced chemiluminescence
technique (ECL) Plus Western Blotting Detection Reagent (GE Healthcare, NJ,
USA) according to the manufacturer’s recommendations, followed by exposure to
x-ray film (Amersham Hyperfilm ECL, GE Healthcare). Quantification was
performed by densitometric analysis using Image J software (available at http://
rsbweb.nih.gov/ij/).
Statistical analysis
The software GraphPad InStat version 4.0 for Windows (GraphPad Software Inc.,
La Jolla, CA, USA) and Statistica version 7.0 for windows (Stat Soft Inc., Tulsa,
USA) were used for all statistical analyzes. Since the assumptions of equality of
variance (Bartlett test) and normal distribution of errors (Kolmogorov-Smirnov
test) were satisfied, two-way ANOVA and Bonferroni’s post hoc tests were carried
out for statistical comparisons. In all cases, statistical significance was defined as a
p value of ,0.05. The data are expressed as mean ¡ SD.
Results
Impact of F in the bone architecture
To assess trabecular and cortical bone morphology after treatment with F we have
conducted tibia and femur micro-CT, respectively. The lumbar vertebra was also
employed for the trabecular study since it has been shown to be a target for the F
effect (S1 Figure) [14]. There were no significant differences in BMD among the
F-treated groups for any bone in either strain (Figs. 1A, 2A, S1A Figure). The
treatment with F did not alter any trabecular or cortical bone parameters in either
strain (Figs. 1 and 2). The tibia BMD was higher in 129P3/J than A/J, independent
of F treatment and dosage (p,0.01, p,0.001 and p,0.05 for control, 10 and
Bone Response to Fluoride
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50 ppmF groups, respectively) while femur BMD was higher only in control
group (p,0.05) (Figs. 1A and 2A). Tibia and vertebral trabecular bone quantity
and structure were also significantly different between the two strains. BS/TV and
BV/TV in 129P3/J were higher than those of the A/J strain for all F treatment
groups, but the difference was only between 10 ppmF-treated groups for tibia
(p,0.01) (Fig. 1B,C) and among all groups for the vertebrae (p,0.01) (S1B,C
Figure). Tb.N was higher in 129P3/J than A/J in control and 10 ppm F-treated
groups for tibia (p,0.01) (Fig. 1G) and in all groups for vertebrae (p,0.01) (S1E
Figure). No differences were found for Tb.Th in tibia whereas it was enhanced in
vertebrae from 10 and 50 ppmF-treated 129P3/J (p,0.005 and p,0.002,
respectively) (S1F Figure). On the other hand, Tb.Sp and Tb.Pf were decreased in
tibia and vertebrae from 129P3/J compared to A/J, independent of treatment
(p,0.01) (Fig. 1E, S1G, H Figure). In addition, all bone cortical parameters were
higher in femur from 129P3/J than A/J mice (Fig. 2). Statistical differences in
B.Pm, T.Pm, MMI and T.Ar were seen among all groups (p,0.01) (Fig. 2B,D,E,F)
and in B.Ar when comparing F-treated groups (Fig. 2C) (p,0.05, p,0.001,
respectively).
F enhances bone formation in 129P3/J but not in A/J
Slight dose-dependent increases in the rate of new bone deposition were observed
for both strains but they were significant only in the 50 ppmF-treated 129P3/J
group when compared to the control and 10 ppmF groups (p,0.01 and p,0.05,
respectively) (Fig. 3A,B). Comparing both strains, the MAR data were
significantly higher in 50 ppmF-treated 129P3/J than the respective A/J (p,0.05)
(Fig. 3A,B).
Plasma ALP activity
We used plasma biochemical assay to investigate alterations in bone modeling and
response to F in both strains. Total ALP activity, as an indirect marker for bone
ALP activity, was unaffected. No statistical differences were observed among the F
treatments for either strain. However, plasma ALP activity in the 129P3/J strain
was significantly higher compared to the A/J strain for all groups (F56.59,
p50.014) (Fig. 4).
Fig. 1. BMD and histomorphometric parameters in trabecular region of tibiae from A/J and 129P3/J mice treated with 0, 10 or 50 ppm F in drinking
water for 8 weeks. Values are mean ¡ SD, n58/group. A5 Bone mineral density (BMD); B5 Specific bone surface (BS/BV); C5 Bone volume fraction
(BV/TV); D5 Bone surface density (BS/TV); E5 Trabecular separation (Tb.Sp); F5 Trabecular thickness (Tb.Th); G5 Trabecular number (Tb.N); H5
Trabecular bone pattern factor (Tb.Pf). *p,0.05, **p,0.01 and *** p,0.001 represents significant differences between strains, for each group. No
statisticallly significant differences were found for each strain after receiving F.
doi:10.1371/journal.pone.0114343.g001
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Fig. 2. BMD and histomorphometric parameters in cortical region of femur from A/J and 129P3/J mice treated with 0, 10 or 50 ppm F. Values are
mean ¡ SD, n58/group. A5 Bone mineral density (BMD); B5 Mean total cross-sectional tissue area (T.Ar); C5 Mean total cross-sectional bone area
(B.Ar); D5 Mean total cross-sectional tissue perimeter T.Pm); E5 Mean total cross-sectional bone perimeter (B.Pm); F5 Mean polar moment of inertia
(MMI). *p,0.05, **p,0.01 and *** p,0.001 represents significant differences between strains, for each group. No statisticallly significant differences were
found for each strain after receiving F.
doi:10.1371/journal.pone.0114343.g002
Fig. 3. Mineral apposition rate (MAR) of femur from A/J and 129P3/J mice after F exposure. (A) Upper
squares: Representative images showing calcein (green) and alizarin complexone (red) labeled mid-
diaphyseal cross-sections of 129P3/J mice. Lower squares: Representative images showing calcein (green)
and alizarin complexone (red) labeled mid-diaphyseal cross-sections of A/J mice. Concentrations of F are
indicated. (B) Values are mean ¡ SD of the measurement distances between the labels, n58/group. *
Represents significant differences between strains for each group (p,0.05); #p,0.01 and ##p,0.001
represent significant differences of control and 10 ppmF-treated 129P3/J versus 50 ppmF-treated 129P3/J
mice, respectively.
doi:10.1371/journal.pone.0114343.g003
Bone Response to Fluoride
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Quantitative proteomic analysis of bone
A total of nine differential analyses for relative protein abundance was performed
with SIEVE software 1.3 (Thermo Fisher Scientific, San Jose, CA), three
comparisons among the F treatments for 129P3/J strain, three among the F
treatments for A/J strain and three between the strains for each F treatment. For
the 129P3/J strain, comparisons between control and experimental groups showed
an increase in level of 29 and 126 proteins in 10 ppmF and 50 ppmF groups,
respectively, while only 1 protein decreased in level in 50 ppmF group (Tables 1,
S1 and S2 Tables). Comparisons of the 129P3/J experimental groups showed an
increase and decrease in the levels of 2 and 3 proteins, respectively, in the
50 ppmF group compared to 10 ppmF group (Table 1 and S3 Table). For the A/J
strain, comparisons of the control and experimental groups showed increases in
levels of 35 and 1 proteins and decreases in levels of 1 and 16 proteins in 10 ppmF
and 50 ppmF groups, respectively (Table 1, S4 and S5 Tables). Comparisons
between F-treated A/J groups showed a decrease in the levels of 15 proteins in
50 ppm F with respect to 10 ppm F group (Table 1 and S6 Table). Comparing the
strains, 163 proteins were more abundant in 129P3/J control group compared to
A/J control group (Table 1 and S7 Table). The 129P3/J 10 ppmF group showed 8
and 6 proteins more and less abundant, respectively, compared to 10 ppmF-
treated A/J group (Table 1 and S8 Table). Finally, 4 proteins were more and only
1 protein was less abundant in the 129P3/J 50 ppmF group compared to its
respective group in A/J (Table 1 and S9 Table).
Proteins with differences in abundance in each comparison were classified
according to their biological process and cellular location (S2–S5 Figures). Several
proteins such as exportin-2, NADPH oxidase 4 (Nox-4), collagen alpha-2(I)
chain, protocadherin beta 15, secreted frizzled-related protein-4 (FRP-4), bone
Fig. 4. Quantification of ALP activity in plasma from A/J and 129P3/J mice treated with 0, 10 or 50 ppm
F in the drinking water for 8 weeks. Results are shown as mean ¡ SD of enzymatic activity (nmol of p-NP
per min per mg of total protein). *Represents significant differences between strains for each group (p,0.05).
No statistical differences were found for each strain after receiving F.
doi:10.1371/journal.pone.0114343.g004
Bone Response to Fluoride
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sialoprotein 2 and bone morphogenetic protein 1 (BMP-1) presented their
abundance increased in bone of control 129P3/J compared to control A/J mice
(Table 2 and S7 Table). The treatment of 129P3/J mice with 50 ppmF promoted
an enhancement of Nox-1, chromodomain helicase DNA binding protein 4
(CDH-4) and -7 (CDH-7), protocadherin beta 9, catenin alpha-2 and
phosphatidylinositol 3-4-5 trisphosphate 5-phosphatase 2 (SHIP-2), aflatoxin B1
aldehyde reductase member 2 (AFB1-AR) and carbonyl reductase NADPH 2
(CBR) compared to untreated control mice (Table 3 and S2 Table). Moreover,
Table 1. Total number of identified bone proteins with differences in abundance in each comparison, by label-free semi-quantitative differential expression
analysis.
Groups of comparison A6B
Total number of proteins
identified
Number of proteins with
differential abundance
Number of proteins (ratio
A/B$1,5)*
Number of proteins (ratio
A/B#0,5)*
129P3/J control 6129P3/J
10 ppm F
1316 29 0 29
129P3/J control 6129P3/J
50 ppm F
1391 127 1 126
129P3/J 10 ppm F 6129P3/J
50 ppm F
1196 5 2 3
A/J control 6A/J 10 ppm F 1455 36 1 35
A/J control 6A/J 50 ppm F 1369 17 16 1
A/J 10 ppm F 6A/J 50 ppm F 1437 15 15 0
129P3/J control 6A/J control 1449 163 163 0
A/J 10 ppm F 6129P3/J
10 ppm F
1321 14 6 8
A/J 50 ppm F 6129P3/J
50 ppm F
644 5 4 1
*Ratio of the relative protein abundance between each comparison. Significant differences in protein abundance were considered when ratio #0.5 or $1.5.
Ratios of #0.5 or $1.5 mean increase or decrease in group B in relation to group A, respectively.
doi:10.1371/journal.pone.0114343.t001
Table 2. Summary of identified proteins with differences in abundance in the comparison between control 129P3/J and control A/J mice.
Acession Numbera Proteinb Ratioc N˚ of peptidesd
Q9ERK4 Exportin-2 1.6 2
Q9JHI8 NADPH oxidase 4 2.7 2
Q01149 Collagen alpha-2(I) chain 1.5 3
Q91Y04 Protocadherin beta 15 1.5 2
P11087 Collagen alpha-1(I) chain 1.5 6
Q9Z1N6 Secreted frizzled-related sequence protein 4 2.3 2
Q61711 Bone sialoprotein 2 1.5 2
P98063 Bone morphogenetic protein 1 1.5 3
aProtein accession numbers from UniProtKB.
bProtein name.
cRatio of the relative protein abundance between (A) control 129P3/J and (B) control A/J mice. Significant differences in protein abundance were considered
when ratio #0.5. Ratio of #0.5 means increase in group B in relation to group A.
dNumber of peptides identified.
doi:10.1371/journal.pone.0114343.t002
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the treatment of A/J with 50 ppmF increased the abundance of SHIP-1 while it
diminished the abundance of exportin-2 (Table 4 and S5 Table).
Confirmation of collagen type I expression by Western blotting
Analysis of collagen type I expression in mouse femur corroborated the
quantitative proteomics data, confirming that there were no statistically
significant differences among the F treatments for either strain (F51.45, p50.262)
but there was a significant increase in the level of collagen type I in 129P3/J
compared to A/J strain (F59.54, p50.006) for all F treatment groups (Fig. 5A,B).
However, it is worth mentioning that quantitative proteomic analysis identified a
significant difference between the strains only for control group.
Table 3. Summary of identified proteins with differences in abundance in the comparison between control 129P3/J and 50 ppmF-treated 129P3/J mice.
Acession Numbera Proteinb Ratioc N˚ of peptidesd
Q9JHI8 NADPH oxidase 4 0.2 2
A2AJK6 Chromodomain-helicase-DNA-binding protein 7 0.5 2
Q6PDQ2 Chromodomain-helicase-DNA-binding protein 4 0.4 4
Q91XZ1 Protocadherin beta 9 0.5 2
Q61301 Catenin alpha-2 0.2 2
Q6P549 Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2 0.4 3
Q8CG76 Aflatoxin B1 aldehyde reductase member 2 0.5 2
P08074 Carbonyl reductase [NADPH] 2 0.5 2
aProtein accession numbers from UniProtKB.
bProtein name.
cRatio of the relative protein abundance between (A) control 129P3/J and (B) control A/J mice. Significant differences in protein abundance were considered
when ratio #0.5. Ratio of #0.5 means increase in group B in relation to group A.
dNumber of peptides identified.
doi:10.1371/journal.pone.0114343.t003
Table 4. Summary of identified proteins with differences in abundance in the comparison between control A/J and 50 ppmF-treated A/J mice.
Acession
Numbera Proteinb Ratioc N˚ of peptidesd
Q7TQC8 Eukaryotic translation initiation factor 2 alpha kinase 3 1.5 2
Q9ERK4 Exportin-2 1.5 2
Q9ES52 Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1 0.4 2
aProtein accession numbers from UniProtKB.
bProtein name.
cRatio of the relative protein abundance between (A) control 129P3/J and (B) control A/J mice. Significant differences in protein abundance were considered
when ratio #0.5. Ratio of #0.5 means increase in group B in relation to group A.
dNumber of peptides identified.
doi:10.1371/journal.pone.0114343.t004
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Discussion
We have shown that A/J and 129P3/J strains present inherent differences in
cortical and trabecular bone and that they are not affected by F treatment. Strain-
specific differences are related to the BMD, bone surface to-tissue volume ratio,
bone volume-to-tissue volume ratio, trabecular number, thickness, and separa-
tion, revealing that A/J mice presented fewer, thinner, less connected, and more
widely spaced trabeculae than those in 129P3/J. Cortical microstructure
parameters in the femur are also diminished in A/J mice. In addition, plasma ALP
activity, an enzyme involved in the mineralization process, is enhanced in 129P3/J
mice. Although exposure to F either failed to change [17] or increased BMD [1, 9],
Fig. 5. Western blot analysis of collagen type I. (A) Representative immunoblot showing collagen type I
levels (upper) in A/J and 129P3/J mice after treatment with 0, 10 or 50 ppmF in drinking water for 8 weeks.
The level of b-tubulin was used as control of sample loading (lower). (B) Values are mean ¡ SD of arbitrary
values of four independent experiments quantified by densitometry analysis using the Image J Software (NIH
Image). Arbitrary values from control A/J were standardized as 1. **Represents significant differences
between strains for each treatment (p,0.01). No statistical differences were found for each strain after
receiving F.
doi:10.1371/journal.pone.0114343.g005
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our data indicate that lumbar vertebrae of A/J mice subjected to mechanical tests
are less resistant than those of 129P3/J mice, regardless of F treatment [13].
Fluorescent bone markers were also used to investigate the dynamic process of
bone formation. In both strains, F promoted a slightly enhanced rate of bone
formation, whereas the treatment of 129P3/J with 50 ppmF group presented
significantly higher MAR, compared to other groups. In combination with
phenytoin, F at 50 ppm in the drinking water promoted an increase of osteocalcin
level, bone ALP specific activity, MAR, bone formation rate and mineralizing
surface in adult rats, showing its effectiveness in stimulating bone formation in
vivo [17]. Although both histomorphometry and MAR data seem to be
contradictory, they do not rule out the possibility that F promotes increased bone
formation in 129P3/J. A possible explanation is based on the fact that the new
Fig. 6. Schemes of the protein-based mechanisms triggered by F in osteoblasts and osteoclasts. Identified proteins with greater abundance in 129P3/
J in comparison to A/J related to bone metabolism are shown in red. (A) Exportin enhances transport of cfab/Runx-2 to the nucleus activating transcription of
collagen type I genes. Cadherins promote intercellular adhesion enhancing osteoblast differentiation. Nox-mediated ROS production enhances RANK
ligand (RANKL) that interacts to its receptor (RANK) to induce osteoclast differentiation. (B) The treatment of 129P3/J with high F promotes enhancement of
Nox, CDH, cadherin, catetin and SHIP while (C) in A/J, F at high dose promotes enhancement of SHIP and reduction of exportin.
doi:10.1371/journal.pone.0114343.g006
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bone may not be totally mineralized, thus compromising the mineral content and
mineral density at that time. Further evaluation of static histomorphometric
parameters over prolonged periods would clarify this matter.
Analysis of LC-ESI MS/MS data revealed differences in protein abundance
among F treatments and between the strains of mice. We have focused on
identified proteins that may be associated with bone cellular metabolism. Collagen
type I (collagen alpha 1 and 2 (I) chain precursors), the major protein of bone,
was more abundant in control 129P3/J mice compared to control A/J mice. These
data were further confirmed by western blotting analysis. Since mechanical
properties of bone tissue depend both on the mineral and matrix (primarily type I
collagen fibrils) constituents, as well as their geometrical arrangement, the greater
abundance of collagen type I in the 129P3/J strain could explain the higher
mechanical strength [13] observed in the femurs of 129P3/J strain compared to
the A/J strain. Also, the increased levels of bone sialoprotein 2, a non-collagen
bone protein that mediates mineral deposition, and bone morphogenetic protein
(BMP)-1 in 129P3/J may contribute to the greater strain-specific bone formation.
These data are consistent with the enhancement of osteoid formation in 129P3/J
mice compared to A/J mice, regardless of F treatment [14].
Exportin-2 (CSE1L) is a protein transport that mediates importin-alpha re-
export from the nucleus to the cytosol after import substrates have been released
into the nucleoplasm [18]. Its abundance in control 129P3/J mice is higher
compared to control A/J mice. Similarly, exportin-1 is involved in the transport of
Cbfa1, a transcriptional factor essential for osteogenesis [19]. In the present study,
the greater abundance of exportin-2 in mature bone of 129P3/J mice may be
evidence that this similar transport factor is involved in the increased strain
dependent-osteoblast differentiation. Although sFRPs are known as negative
modulators of Wnt signaling, some isoforms such as sFRP-4, up-regulated in bone
of control 129P3/J mice compared to A/J mice, were shown to increase b-catenin/
TCR reporter activity followed by ALP activity [20]. Based on these data, this
protein could also be involved in the enhanced bone formation in these mice.
CHD7 was more abundant in 129P3/J mice and, along with CHD4, it was up-
modulated by 50 ppmF. Although no role has been reported for CHD-4 and
CHD-7 in bone, another chromatin remodeling protein, namely CReMM/CHD9,
is expressed by osteoprogenitors cells in mature bone and regulates gene
promoters of osteocalcin [21]. These proteins may play an unexplored role in
mediating transcriptional responses involved in osteoblast function. Moreover,
since cadherin-catenin interactions are crucial for intercellular adhesion [22],
enhanced levels of both in 50 ppmF-treated 129P3/J mice also suggest the positive
impact of F in promoting strain-specific osteoblast differentiation.
Proteins associated with endoplasmatic reticulum (ER) stress, such as
eukaryotic translation initiation factor 2 alpha kinase 3 precursor (eIF2ak3) or
PKR-like endoplasmic reticulum kinase (PERK), were also affected by F. ER stress
during osteoblast differentiation activates the PERK-eIF2a-ATF4 signaling
pathway involved in the promotion of gene expression essential for osteogenesis,
such as osteocalcin and bone sialoprotein [23]. Activation of PERK leads to the
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phosphorylation of the a-subunit of the eukaryotic initiation factor 2 (eIF2),
which reduces protein translation in response to ER stress and also osteoclas-
togenesis [24, 25]. Deficiency of PERK in mice leads to severe neonatal osteopenia
associated with impairment of osteoblast proliferation and differentiation and of
trafficking of type I procollagen [26]. The fact that F decreased the abundance of
PERK when compared to the control A/J group, may indicate both negative and
positive regulation of F in osteoblast differentiation and osteoclastogenesis in this
strain, respectively. No differences in PERK abundance were observed when
comparing other groups.
The treatment with high levels of F increased expression of SHIP1/2 in both A/J
and 129P3/J mice. SHIP dephosphorylates the 59-phosphate group from
phosphatidylinositol-3,4,5-triphosphate (PIP3), the major product of phospha-
tidylinositol 3-kinase (PI3-K), inactivating it. This signaling is implicated in
macrophage-colony stimulating factor and receptor activator of nuclear factor-kB
ligand-mediated osteoclast activation [27]. SHIP-/- mice showed an increase in
numbers of osteoclast precursors in bone marrow, and the number of osteoclasts
was also increased two-fold in bone [28]. The enhancement of SHIP1 abundance
in both strains after F suggests that it down regulates osteoclast differentiation,
regardless the strain.
Another identified protein involved in bone resorption and osteoclast
regulation with differences in abundance is Nox4. NADPH oxidase is an enzyme
system responsible for producing osteoclastic superoxide radicals, promoting
bone resorption [29]. Superoxides may be involved in activation of the
transcription factor NF-kB, which enhances the transcription of genes signaling
osteoclastic activation [30]. This enzyme was found to be more abundant in the
control 129P3/J compared to control A/J mice and was modulated by both levels
of F in that strain. However, F at only 10 ppm increased its abundance in bone of
A/J mice but not in 129P3/J mice. The differential increase in abundance of Nox4
after F treatment in both strains may suggest that it regulates bone remodeling by
enhancing the osteoclast activity in both strain-specific and dose-specific
manners.
Detoxification enzymes, such as AFB1-AR and CBR, showed an increase in
abundance after 50 ppmF treatment in 129P3/J mice compared to the control
group. The CBR was identified in mice lung tissue and may have a role in the
detoxification of xenobiotics and of toxic aldehydes derived from lipid
peroxidation processes [31]. AFB1-AR, in turn, protects the liver against the toxic
effect of aflatoxin B1 (AFB1) [32]. F has been shown to induce lipid peroxidation,
as a dose-dependent toxic effect [33]. Thus, it is possible that F at high doses
induces lipid peroxidation in bone cells, as judged by increased levels of CBR and
AFB1-AR. This suggests that bone cells from 129P3/J but not from A/J mice
require molecular mechanisms to avoid the F-induced toxicity. Recently, it was
suggested that many species have F riboswitches to control the expression of
proteins that soften the deleterious effects of this anion [34]. It is possible that
cells from the A/J and 129P3/J strains differ in the abundance and/or usage of
those F-sensing RNAs.
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These results suggest that F targets molecular mechanisms in both osteoblasts
and osteoclasts. This is consistent with the fact that F acts on osteoblasts and
osteoclasts in vivo and in vitro, by still uncertain mechanisms [5]. F promotes both
osteoblast proliferation and death at low and high concentrations, respectively
[5, 7]. Moreover, the genetic background constitutes an important factor for the
differential effect of F on osteoclasts [35, 36].
Taken together, 129P3/J and A/J mice have intrinsic molecular differences
related to bone metabolism (Fig. 6A). They also differ in response to F. 129P3/J
mice responded similarly at high and low F doses, increasing the level of proteins
involved in bone formation, as well as in bone resorption (Fig. 6B), a similar
profile observed for low F-treated A/J mice. Instead, high F treatment diminishes
level of proteins related to bone remodeling (Fig. 6C). These findings are
consistent with known differences in susceptibility to F effect on mineralized
tissues between these strains. The A/J mouse strain is more sensitive to develop
dental fluorosis and to alterations in the quality of bone, while 129P3/J is less
affected. Proteomic data revealed that bones of A/J mice were highly responsive to
F which altered the abundance of 36 proteins even at the low dose level. At the
higher F exposure level, A/J mice had 17 proteins with differences in expression
compared to the control (untreated) mice. On the other hand, the treatment of
129P3/J mice with low and high doses of F altered 29 and 127 proteins,
respectively. The greater responsiveness to high dose of F suggests that, possibly
due to its resistance, 129P3/J requires a higher dose to trigger cytotoxic, detox and
anabolic responses. Thus, at the higher dose F can stimulate bone formation in
129P3/J mice and either not change or decrease it in A/J mice.
One of the major obstacles of osteoporosis therapy with F is the difficulty in
prospectively identifying which patients might benefit from therapy, since not all
patients respond to F treatment [7]. In the present study, F exposure led to
specific changes in the expression of proteins in both strains evaluated, showing
that there is an influence of genetic background in bone cell responses to F. Based
on its greater F-mediated bone formation, we found the 129P3/J strain to be a
good responder to F. Additional studies should identify, in humans, biomarkers of
bone tissue response to F, with the aim of identifying the best candidates to
receive F therapy in diseases such as osteoporosis.
Supporting Information
S1 Figure. BMD and histomorphometric parameters in trabecular region of 4th
lumbar vertebrae from A/J and 129P3/J mice treated with 0, 10 or 50 ppm F.
Values are mean ¡ SD, n58/group. A5 Bone mineral density (BMD); B5
Specific bone surface BS/BV; C5 Bone volume fraction (BV/TV); D5 Bone
surface density (BS/TV); E5 Trabecular number (Tb.N); F5 Trabecular thickness
(Tb.Th); G5 Trabecular separation (Tb.Sp); H5 Trabecular bone pattern factor
(Tb.Pf). *p,0.05 and **p,0.01 represent significant differences between strains,
for each group.
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S2 Figure. Biological process distribution of the identified bone proteins with
differences in abundance among F treatments in A/J and 129P3/J mice, n58/
group.
doi:10.1371/journal.pone.0114343.s002 (DOCX)
S3 Figure. Cellular distribution of the identified bone proteins with differences in
abundance among F treatments in A/J and 129P3/J mice, n58/group.
doi:10.1371/journal.pone.0114343.s003 (DOCX)
S4 Figure. Biological process distribution of the identified bone proteins with
differences in abundance between the strains (A/J and 129P3/J) for each F
treatment, n58/group.
doi:10.1371/journal.pone.0114343.s004 (DOCX)
S5 Figure. Cellular distribution of the identified bone proteins with differences in
abundance between the strains (A/J and 129P3/J) for each F treatment, n58/
group.
doi:10.1371/journal.pone.0114343.s005 (DOCX)
S1 Table. Complete list of identified proteins with differences in abundance in the
comparison between control 129P3/J and 10 ppmF-treated 129P3/J mice.
doi:10.1371/journal.pone.0114343.s006 (DOCX)
S2 Table. Complete list of identified proteins with differences in abundance in the
comparison between control 129P3/J and 50 ppmF-treated 129P3/J mice.
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S3 Table. Complete list of identified proteins with differences in abundance in the
comparison between 10 ppmF-treated 129P3/J and 50 ppmF-treated 129P3/J
mice.
doi:10.1371/journal.pone.0114343.s008 (DOCX)
S4 Table. Complete list of identified proteins with differences in abundance in the
comparison between control A/J and 10 ppmF– treated mice.
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S5 Table. Complete list of identified proteins with differences in abundance in the
comparison between control A/J and 50 ppmF-treated A/J mice.
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S6 Table. Complete list of identified proteins with differences in abundance in the
comparison between 10 ppmF-treated A/J and 50 ppmF-treated A/J mice.
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S7 Table. Complete list of identified proteins with differences in abundance in the
comparison between control 129P3/J and control A/J mice.
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S8 Table. Complete list of identified proteins with differences in abundance in the
comparison between 10 ppmF-treated 129P3/J and 10 ppmF-treated A/J mice.
doi:10.1371/journal.pone.0114343.s013 (DOCX)
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S9 Table. Complete list of identified proteins with differences in abundance in the
comparison between 50 ppmF-treated 129P3/J and 50 ppmF-treated A/J mice.
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